Skip to main content
Top
Published in: Translational Stroke Research 1/2011

01-03-2011

A Combined Treatment with Taurine and Intra-arterial Thrombolysis in an Embolic Model of Stroke in Rats: Increased Neuroprotective Efficacy and Extended Therapeutic Time Window

Authors: Weihua Guan, Yumei Zhao, Chao Xu

Published in: Translational Stroke Research | Issue 1/2011

Login to get access

Abstract

Combination treatment may target different pathophysiological events following cerebral ischemia thus enhancing the efficacy of treatment in thromboembolic stroke. Taurine confers a neuroprotective effect in the mechanical stroke model. This effect has not been assessed in an embolic stroke model. Here, we sought to evaluate the neuroprotective effect of taurine alone and in combination with thrombolytic therapy to investigate whether combined administration would extend the therapeutic time window without increasing the hemorrhagic transformation in a rat embolic stroke model. Rats were subjected to right embolic middle cerebral artery occlusion and then randomly assigned to the following groups: saline treatment alone at 4 h, urokinase, taurine treatment alone at 4, 6, or 8 h, and the combination of taurine and urokinase at 4, 6, or 8 h after the insult. Brain infarct volume, neurobehavioral outcome, regional cerebral blood flow, intracranial hemorrhage incidence were observed and evaluated. Posttreatment with taurine at 4 or 6 h, urokinase at 4 h or in combination at 4, 6, or 8 h significantly reduced infarct volume and improved neurobehavioral outcome. The combination treatment had better neurobehavioral outcome and smaller infarction volume than urokinase or taurine treatment alone. The clinical outcome correlated well with infarct volume. Together, the present study suggests that administration of taurine after stroke is neuroprotective, seemingly because it reduces the reperfusion damage of urokinase, leading to widen the therapeutic window for the thrombolytic effect of urokinase to 8 h. Thrombolysis can also enhance the neuroprotective effect of taurine. The reduction of inflammatory response, neuron death and inhibition of blood brain barrier (BBB) disruption may underlie the beneficial effects of combination of taurine and urokinase in the treatment of embolic stroke.
Literature
1.
go back to reference Hacke W, Kaste M, Bluhmki E, Brozman M, Dávalos A, Guidetti D, et al. Thrombolysis with alteplase 3 to 4.5 h after acute ischemic stroke. N Engl J Med. 2008;359:1317–29.CrossRefPubMed Hacke W, Kaste M, Bluhmki E, Brozman M, Dávalos A, Guidetti D, et al. Thrombolysis with alteplase 3 to 4.5 h after acute ischemic stroke. N Engl J Med. 2008;359:1317–29.CrossRefPubMed
2.
go back to reference Macleod MR, Davis SM, Mitchell PJ, Gerraty RP, Fitt G, Hankey GJ, et al. Results of a multicentre, randomised controlled trial of intra-arterial urokinase in the treatment of acute posterior circulation ischaemic stroke. Cerebrovasc Dis. 2005;20:12–7.CrossRefPubMed Macleod MR, Davis SM, Mitchell PJ, Gerraty RP, Fitt G, Hankey GJ, et al. Results of a multicentre, randomised controlled trial of intra-arterial urokinase in the treatment of acute posterior circulation ischaemic stroke. Cerebrovasc Dis. 2005;20:12–7.CrossRefPubMed
3.
go back to reference Agarwal P, Kumar S, Hariharan S, Eshkar N, Verro P, Cohen B, et al. Hyperdense middle cerebral artery sign: can it be used to select intra-arterial versus intravenous thrombolysis in acute ischemic stroke? Cerebrovasc Dis. 2004;17:182–90.CrossRefPubMed Agarwal P, Kumar S, Hariharan S, Eshkar N, Verro P, Cohen B, et al. Hyperdense middle cerebral artery sign: can it be used to select intra-arterial versus intravenous thrombolysis in acute ischemic stroke? Cerebrovasc Dis. 2004;17:182–90.CrossRefPubMed
4.
go back to reference Qureshi AI, Ezzeddine MA, Nasar A, Suri MF, Kirmani JF, Janjua N, et al. Is IV tissue plasminogen activator beneficial in patients with hyperdense artery sign? Neurology. 2006;66(8):1171–4.CrossRefPubMed Qureshi AI, Ezzeddine MA, Nasar A, Suri MF, Kirmani JF, Janjua N, et al. Is IV tissue plasminogen activator beneficial in patients with hyperdense artery sign? Neurology. 2006;66(8):1171–4.CrossRefPubMed
5.
go back to reference Labiche LA, Al-Senani F. WojnerAW, et al. Is the benefit of early recanalization sustained at 3 months? A prospective cohort study. Stroke. 2003;34:695–8.CrossRefPubMed Labiche LA, Al-Senani F. WojnerAW, et al. Is the benefit of early recanalization sustained at 3 months? A prospective cohort study. Stroke. 2003;34:695–8.CrossRefPubMed
6.
go back to reference Alexandrov AV, Molina CA, Grotta JC, et al. Ultrasound enhanced systemic thrombolysis for acute ischemic stroke. N Engl J Med. 2004;351:2170–8.CrossRefPubMed Alexandrov AV, Molina CA, Grotta JC, et al. Ultrasound enhanced systemic thrombolysis for acute ischemic stroke. N Engl J Med. 2004;351:2170–8.CrossRefPubMed
7.
go back to reference Brott TG, Haley Jr EC, Levy DE, et al. Urgent therapy for stroke. Part 1. Pilot study of tissue plasminogen activator administered within 90 minutes. Stroke. 1992;23:632–40.PubMed Brott TG, Haley Jr EC, Levy DE, et al. Urgent therapy for stroke. Part 1. Pilot study of tissue plasminogen activator administered within 90 minutes. Stroke. 1992;23:632–40.PubMed
8.
go back to reference Von Krummer R, Hacke W. Safety and efficacy of intravenous tissue plasminogen activator and heparin in acute middle cerebral artery stroke. Stroke. 1992;23:646–52. Von Krummer R, Hacke W. Safety and efficacy of intravenous tissue plasminogen activator and heparin in acute middle cerebral artery stroke. Stroke. 1992;23:646–52.
9.
go back to reference Trouillas P, Nighoghossian N, Getenet JC, et al. Open trial of intravenous tissue plasminogen activator in acute carotid territory stroke: correlations of outcome with clinical and radiological data. Stroke. 1996;27:882–90.PubMed Trouillas P, Nighoghossian N, Getenet JC, et al. Open trial of intravenous tissue plasminogen activator in acute carotid territory stroke: correlations of outcome with clinical and radiological data. Stroke. 1996;27:882–90.PubMed
10.
go back to reference Mattle HP. Intravenous or intra-arterial thrombolysis? It’s time to find the right approach for the right patient. Stroke. 2007;38:2038–40.CrossRefPubMed Mattle HP. Intravenous or intra-arterial thrombolysis? It’s time to find the right approach for the right patient. Stroke. 2007;38:2038–40.CrossRefPubMed
11.
go back to reference Del Zoppo GJ, Higashida RT, Furlan AJ, et al. PROACT: a phase II randomized trial of recombinant pro-urokinase by direct arterial delivery in acute middle cerebral artery stroke. Stroke. 1998;29:4–11.PubMed Del Zoppo GJ, Higashida RT, Furlan AJ, et al. PROACT: a phase II randomized trial of recombinant pro-urokinase by direct arterial delivery in acute middle cerebral artery stroke. Stroke. 1998;29:4–11.PubMed
12.
go back to reference Furlan A, Higashida R, Wechsler L, et al. Intra-arterial pro-urokinase for acute ischemic stroke: the PROACT II study: a randomized controlled trial. JAMA. 1999;282:2003–11.CrossRefPubMed Furlan A, Higashida R, Wechsler L, et al. Intra-arterial pro-urokinase for acute ischemic stroke: the PROACT II study: a randomized controlled trial. JAMA. 1999;282:2003–11.CrossRefPubMed
13.
go back to reference Zhang L, Zhang ZG, Zhang CL, Zhang RL, Chopp M. Intravenous administration of a GPIIb/IIIa receptor antagonist extends the therapeutic window of intra-arterial tenecteplase-tissue plasminogen activator in a rat stroke model. Stroke. 2004;35:2890–095.CrossRefPubMed Zhang L, Zhang ZG, Zhang CL, Zhang RL, Chopp M. Intravenous administration of a GPIIb/IIIa receptor antagonist extends the therapeutic window of intra-arterial tenecteplase-tissue plasminogen activator in a rat stroke model. Stroke. 2004;35:2890–095.CrossRefPubMed
14.
go back to reference Sun M, Xu C. Neuroprotective mechanism of taurine due to up-regulating calpastatin and down-regulating calpain and caspase-3 during focal cerebral ischemia cellular and molecular neurobiology. Cell Mol Neurobiol. 2008;28:593–611.CrossRefPubMed Sun M, Xu C. Neuroprotective mechanism of taurine due to up-regulating calpastatin and down-regulating calpain and caspase-3 during focal cerebral ischemia cellular and molecular neurobiology. Cell Mol Neurobiol. 2008;28:593–611.CrossRefPubMed
15.
go back to reference Asahi M, Asahi K, Wang XY, Lo EH. Reduction of tissue plasminogen activator-induced hemorrhage and brain injury by free radical spin trapping after embolic focal cerebral ischemia in rats. J Cereb Blood Flow Metab. 2000;20:452–7.CrossRefPubMed Asahi M, Asahi K, Wang XY, Lo EH. Reduction of tissue plasminogen activator-induced hemorrhage and brain injury by free radical spin trapping after embolic focal cerebral ischemia in rats. J Cereb Blood Flow Metab. 2000;20:452–7.CrossRefPubMed
16.
go back to reference Paxinos G, Watson C. The Rat Brain Stereotaxic Coordinates. 2nd ed. Orlando: Academic Press; 1986. Paxinos G, Watson C. The Rat Brain Stereotaxic Coordinates. 2nd ed. Orlando: Academic Press; 1986.
17.
go back to reference Shuaib A, Yang Y, Siddiqui M, Kalra J. Intraarterial urokinase produces significant attenuation of infarction volume in an embolic focal ischemia model. Exp Neurol. 1998;154:330–5.CrossRefPubMed Shuaib A, Yang Y, Siddiqui M, Kalra J. Intraarterial urokinase produces significant attenuation of infarction volume in an embolic focal ischemia model. Exp Neurol. 1998;154:330–5.CrossRefPubMed
18.
go back to reference Yang Y, Li Q, Shuaib A. Enhanced neuroprotection and reduced hemorrhagic incidence in focal cerebral ischemia of rat by low dose combination therapy of urokinase and topiramate. Neuropharmacology. 2000;39:881–8.CrossRefPubMed Yang Y, Li Q, Shuaib A. Enhanced neuroprotection and reduced hemorrhagic incidence in focal cerebral ischemia of rat by low dose combination therapy of urokinase and topiramate. Neuropharmacology. 2000;39:881–8.CrossRefPubMed
19.
go back to reference Bederson JB, Pitts LH, Tsuji M, Nishimura MC, Davis RL, Bartkowski H. Rat middle cerebral artery occlusion: evaluation of the model and development of a neurologic examination. Stroke. 1986;17:472–6.PubMed Bederson JB, Pitts LH, Tsuji M, Nishimura MC, Davis RL, Bartkowski H. Rat middle cerebral artery occlusion: evaluation of the model and development of a neurologic examination. Stroke. 1986;17:472–6.PubMed
20.
go back to reference Lin TN, He YY, Wu G, Khan M, Hsu CY. Effects of brain edema on infarct volume in a focal cerebral ischemia model in rats. Stroke. 1993;24:117–21.PubMed Lin TN, He YY, Wu G, Khan M, Hsu CY. Effects of brain edema on infarct volume in a focal cerebral ischemia model in rats. Stroke. 1993;24:117–21.PubMed
21.
go back to reference Zhang JW, Gottschall PE. Zymographic measurement of gelatinase activity in brain tissue after detergent extraction and affinity-support purification. J Neurosci Methods. 1997;76:15–20.CrossRefPubMed Zhang JW, Gottschall PE. Zymographic measurement of gelatinase activity in brain tissue after detergent extraction and affinity-support purification. J Neurosci Methods. 1997;76:15–20.CrossRefPubMed
22.
go back to reference Kleiner DE, Stetler-Stevenson WG. Quantitative zymography: detection of pictogram quantities of gelatinase. Anal Biochem. 1994;218:325–9.CrossRefPubMed Kleiner DE, Stetler-Stevenson WG. Quantitative zymography: detection of pictogram quantities of gelatinase. Anal Biochem. 1994;218:325–9.CrossRefPubMed
23.
go back to reference Zhang ZG, Chopp M. Measurement of myeloperoxidase immunoreactive cells in ischemic brain after transient middle cerebral artery occlusion in the rat. Neurosci Res Comm. 1997;20:85–91.CrossRef Zhang ZG, Chopp M. Measurement of myeloperoxidase immunoreactive cells in ischemic brain after transient middle cerebral artery occlusion in the rat. Neurosci Res Comm. 1997;20:85–91.CrossRef
24.
go back to reference Lima L, Obregon F, Cubillos S, Fazzino F, Jaimes I. Taurine as a micronutrient in development and regeneration of the central nervous system. Nutr Neurosci. 2001;4:439–43.PubMed Lima L, Obregon F, Cubillos S, Fazzino F, Jaimes I. Taurine as a micronutrient in development and regeneration of the central nervous system. Nutr Neurosci. 2001;4:439–43.PubMed
25.
go back to reference Matsumoto K, Ueda S, Hashimoto T, Kuriyama K. Ischemic neuronal injury in the rat hippocampus following transient forebrain ischemia: evaluation using in vivo microdialysis. Brain Res. 1991;543:236–42.CrossRefPubMed Matsumoto K, Ueda S, Hashimoto T, Kuriyama K. Ischemic neuronal injury in the rat hippocampus following transient forebrain ischemia: evaluation using in vivo microdialysis. Brain Res. 1991;543:236–42.CrossRefPubMed
26.
go back to reference Wu JY, Lin CT, Johanssen FF, Liu JW. Taurine neurons in rat hippocampal formation are relatively inert to cerebral ischemia. Adv Exp Med Biol. 1994;359:289–98.PubMed Wu JY, Lin CT, Johanssen FF, Liu JW. Taurine neurons in rat hippocampal formation are relatively inert to cerebral ischemia. Adv Exp Med Biol. 1994;359:289–98.PubMed
27.
go back to reference Shuaib A. The role of taurine in cerebral ischemia: studies in transient forebrain ischemia and embolic focal ischemia in rodents. Adv Exp Med Biol. 2003;526:421–31.PubMed Shuaib A. The role of taurine in cerebral ischemia: studies in transient forebrain ischemia and embolic focal ischemia in rodents. Adv Exp Med Biol. 2003;526:421–31.PubMed
28.
go back to reference Sanberg PR, Willow M. Dose-dependent effects of taurine on convulsions induced by hypoxia in the rat. Neurosci Lett. 1980;16:297–300.CrossRefPubMed Sanberg PR, Willow M. Dose-dependent effects of taurine on convulsions induced by hypoxia in the rat. Neurosci Lett. 1980;16:297–300.CrossRefPubMed
29.
go back to reference Schurr A, Tseng MT, West CA, Rigor BM. Taurine improves the recovery of neuronal function following cerebral hypoxia: an in vitro study. Life Sci. 1987;40:2059–66.CrossRefPubMed Schurr A, Tseng MT, West CA, Rigor BM. Taurine improves the recovery of neuronal function following cerebral hypoxia: an in vitro study. Life Sci. 1987;40:2059–66.CrossRefPubMed
30.
go back to reference Schuller-Levis GB, Park E. Taurine and its chloramine: modulators of immunity. Neurochem Res. 2004;29:117–26.CrossRefPubMed Schuller-Levis GB, Park E. Taurine and its chloramine: modulators of immunity. Neurochem Res. 2004;29:117–26.CrossRefPubMed
31.
go back to reference Guz G, Oz E, Lortlar N, Ulusu NN, Demirogullari B, Omeroglu S, et al. The effect of taurine on renal ischemia/reperfusion injury. Amino Acids. 2007;32:405–11.CrossRefPubMed Guz G, Oz E, Lortlar N, Ulusu NN, Demirogullari B, Omeroglu S, et al. The effect of taurine on renal ischemia/reperfusion injury. Amino Acids. 2007;32:405–11.CrossRefPubMed
32.
go back to reference Raschke P, Massoudy P, Becker BF. Taurine protects the heart from neutrophil-induced reperfusion injury. Free Radic Biol Med. 1995;19:461–71.CrossRefPubMed Raschke P, Massoudy P, Becker BF. Taurine protects the heart from neutrophil-induced reperfusion injury. Free Radic Biol Med. 1995;19:461–71.CrossRefPubMed
33.
go back to reference Giriş M, Depboylu B, Doğru-Abbasoğlu S, Erbil Y, Olgaç V, Aliş H, et al. Effect of taurine on oxidative stress and apoptosis-related protein expression in trinitrobenzene sulphonic acid-induced colitis. Clin Exp Immunol. 2008;152:102–10.CrossRefPubMed Giriş M, Depboylu B, Doğru-Abbasoğlu S, Erbil Y, Olgaç V, Aliş H, et al. Effect of taurine on oxidative stress and apoptosis-related protein expression in trinitrobenzene sulphonic acid-induced colitis. Clin Exp Immunol. 2008;152:102–10.CrossRefPubMed
34.
go back to reference Marcinkiewicz J, Kurnyta M, Biedroń R, Bobek M, Kontny E, Maśliński W. Anti-inflammatory effects of taurine derivatives (taurine chloramine, taurine bromamine, and taurolidine) are mediated by different mechanisms. Adv Exp Med Biol. 2006;583:481–92.CrossRefPubMed Marcinkiewicz J, Kurnyta M, Biedroń R, Bobek M, Kontny E, Maśliński W. Anti-inflammatory effects of taurine derivatives (taurine chloramine, taurine bromamine, and taurolidine) are mediated by different mechanisms. Adv Exp Med Biol. 2006;583:481–92.CrossRefPubMed
35.
go back to reference Zhao RZ, Wang S, Kim HY, Storrie H, Rosen BR, Mooney DJ, et al. Role of matrix metalloproteinases in delayed cortical responses after stroke. Nat Med. 2006;12:441–5.CrossRefPubMed Zhao RZ, Wang S, Kim HY, Storrie H, Rosen BR, Mooney DJ, et al. Role of matrix metalloproteinases in delayed cortical responses after stroke. Nat Med. 2006;12:441–5.CrossRefPubMed
36.
go back to reference Gidday JM, Gasche YG, Copin JC, Shah AR, Perez RS, Shapiro SD, et al. Leukocyte-derived matrix metalloproteinase-9 mediates blood-brain barrier breakdown and is proinflammatory after transient focal cerebral ischemia. Am J Physiol Heart Circ Physiol. 2005;289:H558–68.CrossRefPubMed Gidday JM, Gasche YG, Copin JC, Shah AR, Perez RS, Shapiro SD, et al. Leukocyte-derived matrix metalloproteinase-9 mediates blood-brain barrier breakdown and is proinflammatory after transient focal cerebral ischemia. Am J Physiol Heart Circ Physiol. 2005;289:H558–68.CrossRefPubMed
37.
go back to reference Matsuo Y, Onodera H, Shiga Y, Nakamura M, Ninomiya M, Kihara T, et al. Correlation between myeloperoxidase-quantified neutrophil accumulation and ischemic brain injury in the rat. Effects of neutrophil depletion. Stroke. 1994;25:1469–75.PubMed Matsuo Y, Onodera H, Shiga Y, Nakamura M, Ninomiya M, Kihara T, et al. Correlation between myeloperoxidase-quantified neutrophil accumulation and ischemic brain injury in the rat. Effects of neutrophil depletion. Stroke. 1994;25:1469–75.PubMed
38.
go back to reference Ogawa A, Mori E, Minematsu K, Taki W, Takahashi A, Nemoto S, et al. Randomized trial of intraarterial infusion of urokinase within 6 hours of middle cerebral artery stroke: the middle cerebral artery embolism local fibrinolytic intervention trial (MELT) Japan. Stroke. 2007;38(10):2633–9.CrossRefPubMed Ogawa A, Mori E, Minematsu K, Taki W, Takahashi A, Nemoto S, et al. Randomized trial of intraarterial infusion of urokinase within 6 hours of middle cerebral artery stroke: the middle cerebral artery embolism local fibrinolytic intervention trial (MELT) Japan. Stroke. 2007;38(10):2633–9.CrossRefPubMed
39.
go back to reference Lee DH, Jo KD, Kim HG, Choi SJ, Jung SM, Ryu DS, et al. Local intraarterial urokinase thrombolysis of acute ischemic stroke with or without intravenous abciximab: a pilot study. J Vasc Interv Radiol. 2002;13(8):769–74.CrossRefPubMed Lee DH, Jo KD, Kim HG, Choi SJ, Jung SM, Ryu DS, et al. Local intraarterial urokinase thrombolysis of acute ischemic stroke with or without intravenous abciximab: a pilot study. J Vasc Interv Radiol. 2002;13(8):769–74.CrossRefPubMed
40.
go back to reference Yu YY, Niu L, Gao L, Zhao ZW, Deng JP, Qu YZ, et al. Intraarterial thrombolysis and stent placement for acute basilar artery occlusion. J Vasc Interv Radiol. 2010;21(9):1359–63.CrossRefPubMed Yu YY, Niu L, Gao L, Zhao ZW, Deng JP, Qu YZ, et al. Intraarterial thrombolysis and stent placement for acute basilar artery occlusion. J Vasc Interv Radiol. 2010;21(9):1359–63.CrossRefPubMed
41.
go back to reference Arnold M, Fischer U, Schroth G, Nedeltchev K, Isenegger J, Remonda L, et al. Intra-arterial thrombolysis of acute iatrogenic intracranial arterial occlusion attributable to neuroendovascular procedures or coronary angiography. Stroke. 2008;39(5):1491–5.CrossRefPubMed Arnold M, Fischer U, Schroth G, Nedeltchev K, Isenegger J, Remonda L, et al. Intra-arterial thrombolysis of acute iatrogenic intracranial arterial occlusion attributable to neuroendovascular procedures or coronary angiography. Stroke. 2008;39(5):1491–5.CrossRefPubMed
Metadata
Title
A Combined Treatment with Taurine and Intra-arterial Thrombolysis in an Embolic Model of Stroke in Rats: Increased Neuroprotective Efficacy and Extended Therapeutic Time Window
Authors
Weihua Guan
Yumei Zhao
Chao Xu
Publication date
01-03-2011
Publisher
Springer-Verlag
Published in
Translational Stroke Research / Issue 1/2011
Print ISSN: 1868-4483
Electronic ISSN: 1868-601X
DOI
https://doi.org/10.1007/s12975-010-0050-4

Other articles of this Issue 1/2011

Translational Stroke Research 1/2011 Go to the issue